BioSpace News Archive

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023.

Changing Patient Care Through Innovation Nihon Kohden America, Inc., a U.S. market leader in precision medical products and services, is happy to introduce CoMET, a tool that can provide an early indication of future risk of catastrophic clinical events.

Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.

EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in individuals with dementia with Lewy bodies (DLB).

Artificial intelligence can reconstruct coarsely-sampled, rapid magnetic resonance imaging scans into high-quality images with similar diagnostic value as those generated through traditional MRI, according to a new study by the NYU Grossman School of Medicine and Meta AI Research.

Augmedix Inc. (Nasdaq: AUGX) today announced that its leadership team will participate in the Maxim Group Virtual Healthcare IT Conference on Wednesday, January 25, 2023.

NexImmune, Inc. (Nasdaq: NEXI) today announced the publication of an article highlighting the Company’s AIM platform as a new immunotherapy approach for viral diseases in Frontiers in Medicine.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of 96,700 restricted stock units to four new employees.

Taiho Oncology, Inc. today announced the publication of results from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in the January 19, 2023 issue of The New England Journal of Medicine (NEJM)